MM18

ALLG MM18

Single arm, multicentre study evaluating the safety and efficacy of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM).

Disease:

Multiple Myeloma (MM)

Summary:

Multiple myeloma (MM) is a cancer of plasma cells which produce antibodies, an important immune system product. The abnormal antibodies are produced in excess amount, and can accumulate in the kidney (causing kidney failure), in bones (causing fractures and leeching of calcium into the blood) and bone marrow (causing low blood counts).

Though there are treatments for multiple myeloma, it is not curable and the disease will come back.

This trial is for patients who have received treatment for their myeloma before, and the disease has continued to grow or has returned. Patients will receive thalidomide and dexamethasone, and the new drug carfilzomib. Carflizomib works by stopping the cancerous plasma cells from multiplying, and is given through an intravenous drip

The aim of the trial is to see how effective this combination with carfilzomib is in treating myeloma.

Eligibility:

Include, but not limited to, the following:

Include, but not limited to, the following:
- Patients must be aged 18 years of age or above
- A diagnosis of multiple myeloma that has continued to grow (refractory) or returned (relapsed) after at least one, but no more than three, lines of treatment
- No other active cancers (other than some cancers cured with minor operations like skin cancer)
- No other major health problems

Contact person:

Louise Hay

Email louise.hay@health.wa.gov.au

Phone 6457 7600

Principal Investigator:

Dr Bradley Augustson

08 6457 7600

Sponsor:

Australasian Leukaemia and Lymphoma Group (ALLG)

Phase:

II

Protocol Number:

ALLG MM18

Trial Registration Number:

ACTRN12615000818538

Clinical Trials.gov

ANZ Clinical Trial Registry